In Brief: RSV Vaccine (Arexvy) for Ages 18-49
Abstract
The FDA has expanded the licensed use of the recombinant respiratory syncytial virus (RSV) vaccine Arexvy (GSK) to include adults 18-49 years old. Arexvy and the two other available RSV vaccines, Abrysvo and mResvia, are now all licensed for prevention of RSV lower respiratory tract disease in persons ≥60 years old and in those 18-59 years old who are at increased risk of lower respiratory tract disease caused by RSV.1 Abrysvo is also licensed for use in pregnant women at 32-36 weeks' gestation to prevent RSV-associated respiratory tract disease in their infants from birth to 6 months.
Fields of Study & Subjects
Viral Infections and Immunology Research
Respiratory viral infections research
Animal Virus Infections Studies
Publication details
- Journal / source
- The medical letter on drugs and therapeutics/The medical letter
- Publisher
- The Medical Letter, Inc.
- Volume
- 68
- Issue
- 1754
- Pages
- 77–78
- Publication date
- 11 May 2026
- Language
- EN